Choroideremia is a rare inherited retinal disease caused by mutations in the CHM gene on the X chromosome, leading to progressive vision loss that typically begins with night blindness in childhood and advances toward severe visual impairment or blindness by middle age. Because it follows an X-linked inheritance pattern, the condition overwhelmingly affects males, though female carriers can show retinal changes of their own. The disease has no approved cure yet, but gene therapy trials have produced measurable, if modest, improvements in vision, and the condition’s relatively simple genetic architecture makes it one of the more promising targets for genetic treatment in ophthalmology.
What Causes Choroideremia
The root cause is a mutation in the CHM gene, which provides instructions for making a protein called Rab escort protein 1, or REP-1. This protein plays a housekeeping role in cells: it helps attach small lipid tags to a family of signaling molecules called Rab GTPases, a process that allows those molecules to anchor to cell membranes and do their jobs directing internal cargo transport.1PubMed Central. Choroideremia: Update On Clinical Features And Emerging Treatments Without REP-1, Rab GTPases go untagged, and the cell’s internal trafficking system gradually breaks down.2PubMed Central. Rab GTPase prenylation hierarchy and its potential role in choroideremia disease
Most cells in the body can compensate because they also produce a backup protein, REP-2, which can fill in for its missing cousin. But the retina appears to be uniquely dependent on REP-1. The retinal pigment epithelium (RPE), the thin cell layer that nourishes and maintains the light-sensing photoreceptors, is particularly vulnerable. When REP-1 is absent, RPE cells degrade first, and photoreceptors follow.3PubMed Central. Multimodal Imaging of Photoreceptor Structure in Choroideremia Mouse models have confirmed this sequence: when researchers knocked out the CHM gene only in RPE cells, photoreceptor death accelerated compared to animals where only the photoreceptors themselves lacked the gene.4PubMed Central. Retinal pigment epithelium defects accelerate photoreceptor degeneration in cell type-specific knockout mouse models of choroideremia
The types of mutations found in the CHM gene are varied. Researchers have catalogued large deletions that wipe out much of the gene, smaller deletions that shift the reading frame, and point mutations that insert premature stop signals. In most cases, the result is the same: the cell either makes a truncated, nonfunctional version of REP-1 or produces none at all.5PLOS ONE. A Comprehensive Analysis of Choroideremia: From Genetic Characterization to Clinical Practice
Who Gets Choroideremia and How It Is Inherited
Because the CHM gene sits on the X chromosome, the inheritance pattern is straightforward for males: a boy who inherits a mutated copy from his mother has no second X chromosome to supply a working version, so he develops the disease. Estimates of prevalence vary but generally fall around 1 in 50,000 to 100,000 people. A mother who carries one mutated copy has a 50 percent chance of passing it to each son, and daughters who inherit the mutation become carriers themselves.
The practical implication for families is that genetic testing can identify carriers before symptoms develop. Modern sequencing methods can pinpoint the exact mutation in a family, which is useful both for confirming the diagnosis and for family planning. Prenatal genetic testing has been applied successfully in affected families.6PubMed Central. Diagnosis for choroideremia in a large Chinese pedigree by next‑generation sequencing (NGS) and non‑invasive prenatal testing (NIPT)
What Female Carriers Experience
The old textbook view held that female carriers of choroideremia are asymptomatic. That turns out to be an oversimplification. In one study that examined all 11 female carriers in a cohort, every single one showed retinal abnormalities on fundus examination, ranging from mild pigment changes in the peripheral retina to widespread deposits and depigmented areas reaching the central macula.7PubMed. Retinal dystrophy and subretinal drusenoid deposits in female choroideremia carriers For most carriers, these changes do not cause significant vision problems. But a subset of carriers does develop meaningful visual symptoms.
The mechanism behind symptomatic carriers is an active area of research. One hypothesis suggests that in certain women, both copies of the CHM gene are active in some cells, producing both the normal REP-1 protein and the mutant version. The mutant protein may interfere with the normal version’s function, essentially sabotaging the cell’s protein-processing machinery from within.8PubMed Central. A Novel Hypothesis on Choroideremia-Manifesting Female Carriers: Could CHM In-Frame Variants Exert a Dominant Negative Effect? A Case Report If confirmed, this would explain why some carriers fare worse than X-chromosome inactivation patterns alone would predict.
Symptoms and the Typical Timeline
The first symptom boys with choroideremia usually notice is difficulty seeing in the dark, often during their first or second decade of life. By their twenties, peripheral vision loss becomes apparent.9PubMed Central. Choroideremia: Retinal Degeneration With an Unmet Need The visual field narrows progressively, creating a tunnel-vision effect. Central vision, the sharp sight you use for reading and recognizing faces, is typically the last to go. Many affected men retain functional central vision into their forties or even fifties, though the surrounding visual field may be severely constricted by then.
The reason central vision holds out so long relates to the anatomy of disease progression. The degeneration begins in the mid-periphery of the retina and works inward. Imaging studies show that the surviving island of retinal tissue centers on a point just to the side of the fovea, the retina’s most densely packed spot.10PubMed Central. A Qualitative and Quantitative Assessment of Fundus Autofluorescence Patterns in Patients With Choroideremia Research tracking the area of surviving RPE found that it shrinks by roughly 7.7 percent of the remaining area per year, following a logarithmic pattern. The estimated half-life of the surviving retinal island is about nine years.10PubMed Central. A Qualitative and Quantitative Assessment of Fundus Autofluorescence Patterns in Patients With Choroideremia
Rod photoreceptors, the cells responsible for dim-light vision, are hit early and hard. Even the least affected individuals in one study already showed substantial rod sensitivity loss at baseline. Cone-driven responses, which underpin daytime and color vision, remained comparable to normal until late stages of the disease.11Ovid. THE NATURAL HISTORY OF FULL-FIELD STIMULUS THRESHOLD DECLINE IN CHOROIDEREMIA The practical consequence is that affected men often function reasonably well in good lighting long after their night vision has vanished.
How Choroideremia Gets Diagnosed and Misdiagnosed
Getting the right diagnosis can take time. Choroideremia shares several hallmark features with retinitis pigmentosa (RP): night blindness, shrinking visual fields, declining acuity, and visible retinal degeneration. Studies have estimated that roughly 6 percent of people initially diagnosed with RP-related conditions actually have choroideremia, and conversely, about a quarter of clinical choroideremia diagnoses may turn out to be something else, including RP.12Journal of Korean Medical Science. Clinical Manifestations and Genetic Analysis of 5 Korean Choroideremia Patients Initially Diagnosed With Retinitis Pigmentosa
The distinguishing feature on clinical exam is the pattern of retinal atrophy. Choroideremia typically produces scalloped areas of chorioretinal loss starting in the mid-periphery, with the macula preserved until late. RP, by contrast, often shows bone-spicule pigment deposits and a different pattern of thinning. But early-stage disease can look ambiguous, and fundus appearance varies enough in both conditions that visual inspection alone is unreliable. Genetic testing has become the definitive diagnostic step: confirming a CHM mutation settles the question.12Journal of Korean Medical Science. Clinical Manifestations and Genetic Analysis of 5 Korean Choroideremia Patients Initially Diagnosed With Retinitis Pigmentosa
Several imaging techniques support monitoring once the diagnosis is confirmed. Fundus autofluorescence (FAF) maps the surviving RPE by detecting a naturally fluorescent pigment in those cells, giving clinicians a clear picture of how much functional retina remains and how quickly it is receding. Optical coherence tomography (OCT) provides cross-sectional views of the retinal layers to assess structural integrity. And newer approaches using adaptive optics scanning light ophthalmoscopy can resolve individual cells, revealing subtle phenotypic differences that standard imaging misses.13PubMed Central. FOVEAL PHENOTYPES IN CHOROIDEREMIA ON ADAPTIVE OPTICS SCANNING LIGHT OPHTHALMOSCOPY These quantitative measures of cell-level structure correlate with both the structural and functional severity of the disease, making them potentially useful for tracking treatment responses.14PubMed Central. High-Resolution Adaptive Optics Retinal Imaging of Cellular Structure in Choroideremia
Gene Therapy and Where It Stands
Choroideremia has been considered a strong candidate for gene therapy for several reasons. The faulty gene’s coding sequence is small enough to fit comfortably inside an adeno-associated virus (AAV) delivery vehicle, with room left over for the regulatory elements needed to drive expression.15PubMed Central. Is subretinal AAV gene replacement still the only viable treatment option for choroideremia? AAV serotype 2 efficiently enters both RPE cells and photoreceptors when injected beneath the retina.16PubMed Central. Functional expression of Rab escort protein 1 following AAV2-mediated gene delivery in the retina of choroideremia mice and human cells ex vivo And because the disease progresses slowly and central retina survives for decades, there is a wide treatment window during which viable cells remain to be rescued.
Multiple clinical trials have tested a therapy called timrepigene emparvovec (also known as AAV2-REP1). The treatment is delivered via subretinal injection following a vitrectomy, a surgical procedure that removes the gel inside the eye to allow access to the retina. The pivotal phase 3 trial did not meet its primary endpoint, which was a gain of three lines on a visual acuity chart. However, a statistically significant proportion of treated patients did gain two lines of acuity, one of the trial’s secondary endpoints.17PubMed Central. Gene therapy for choroideremia: progress, potential and pitfalls
A recent systematic review and meta-analysis pooling data across gene therapy trials for choroideremia found consistent, statistically significant improvements across several measures. Retinal sensitivity improved by an average of about 0.78 decibels. Visual acuity improved by roughly three letters on a standardized eye chart, with larger gains seen at the 24-month mark. Structural measures also moved in the right direction: treated eyes showed reduced RPE degeneration and increased thickness of the choroidal layer beneath the retina. Treatment-related adverse events occurred in about 35 percent of participants, but the majority were mild or moderate and related to the surgical procedure itself rather than the gene therapy vector. Serious adverse events occurred in fewer than one in five treated patients.18The Lancet. Efficacy and safety of adeno-associated virus-mediated gene therapy for choroideremia: a systematic review and meta-analysis
These results are real but modest, and it is worth being honest about the gap between the hope surrounding gene therapy and the clinical reality so far. A gain of three letters is not perceptible to most patients in daily life. The more meaningful finding may be the slowdown in retinal degeneration, which could translate into years of preserved functional vision. But we do not yet have the long-term follow-up data to confirm that.
The Surgery Itself
Delivering gene therapy to the retina is not like taking a pill. It requires delicate eye surgery. After performing a vitrectomy, the surgeon creates a small, intentional detachment of the retina by injecting the viral vector solution into the subretinal space. This controlled bleb of fluid separates the photoreceptors from the RPE just long enough for the viral particles to transduce the target cells. The retina then reattaches on its own as the fluid is absorbed.
Reassuringly, treated eyes have shown recovery of visual acuity and retinal thickness back to baseline within about a month of the procedure.19Eye. Technique of retinal gene therapy: delivery of viral vector into the subretinal space One question that has been explored is whether you can safely treat both eyes. The GEMINI study tested sequential bilateral injections and found that visual acuity was generally maintained in both eyes regardless of the time gap between surgeries. Bilateral treatment was well tolerated, with a serious surgical complication rate under 8 percent.20PubMed. An Open-Label Phase II Study Assessing the Safety of Bilateral, Sequential Administration of Retinal Gene Therapy in Participants with Choroideremia: The GEMINI Study For a disease that inevitably affects both eyes, the feasibility of treating both sides is a significant practical development.
Beyond Gene Replacement
Gene therapy is the most advanced approach, but it is not the only strategy being explored. One alternative is translational read-through inducing drugs (TRIDs), small molecules that coax the ribosome into reading past premature stop codons and producing a full-length protein. Because about 30 percent of choroideremia cases are caused by nonsense mutations (those premature stop signals), this approach would theoretically apply to a sizable fraction of patients. A drug called PTC124 (ataluren) showed promise in a zebrafish model of choroideremia but produced only a non-significant trend toward functional rescue in human cells. It failed to produce detectable REP-1 protein in patient-derived cells even when combined with other drugs designed to help, suggesting the road from lab bench to clinic for read-through drugs remains long.21Scientific Reports. The effect of PTC124 on choroideremia fibroblasts and iPSC-derived RPE raises considerations for therapy
Stem cell therapy is another line of investigation, aimed at replacing dead or dying RPE cells with healthy lab-grown ones. The concept is especially appealing for patients whose disease has progressed beyond the point where gene therapy would help, since there is no use delivering a working gene to cells that no longer exist. This approach is earlier in development for choroideremia specifically, though RPE cell transplantation has been tested in other retinal diseases.22PubMed Central. Choroideremia: from genetic and clinical phenotyping to gene therapy and future treatments
Living with Choroideremia Before and Between Treatments
For most people with choroideremia today, there is no treatment that stops or reverses the disease. Day-to-day management centers on adapting to progressive vision loss. Night-vision aids, high-contrast settings on devices, and orientation and mobility training become important tools. Sunglasses and brimmed hats in bright light help reduce glare, which can be disabling when the retina has lost its normal contrast-handling ability.
Despite the obvious impact of progressive blindness on daily life, the formal research on quality of life in choroideremia is remarkably thin. A literature search conducted several years ago failed to turn up any published studies directly evaluating quality of life in choroideremia patients, and no studies assessing the economic burden of the disease were found either.9PubMed Central. Choroideremia: Retinal Degeneration With an Unmet Need This gap matters. Without formal quality-of-life data, it is harder to make the case for treatment funding, harder to design clinical trials that measure outcomes patients actually care about, and harder to understand the full scope of what the disease takes from people.
The slow but relentless pace of choroideremia creates a particular kind of psychological challenge. Affected men often spend decades watching their visual field contract, knowing where the trajectory leads but unable to predict exactly when functional independence will be compromised. Support organizations and patient registries have become important both for connecting families and for facilitating research recruitment. Because the condition is rare, many patients have never met another person with the same diagnosis, and the sense of isolation can compound the difficulty of adaptation.
Timing of Treatment and the Window Problem
One of the hardest practical questions in choroideremia treatment is when to intervene. Gene therapy aims to preserve surviving retinal cells, so treating too late, after most cells have died, limits the potential benefit. But treating too early means operating on an eye that may still have decades of functional vision ahead, with all the surgical risks that entails. The logarithmic degeneration pattern documented in imaging studies, where the surviving retinal area shrinks by roughly 7.7 percent per year, offers a framework for timing, but it is a statistical average rather than a personalized prediction.10PubMed Central. A Qualitative and Quantitative Assessment of Fundus Autofluorescence Patterns in Patients With Choroideremia
Functional testing adds another dimension. Measures of scotopic (dim-light) sensitivity are already severely impaired even in early disease, but photopic (daylight) sensitivity and visual acuity can remain normal until very late. This means standard visual acuity, the letter chart at your eye doctor’s office, is a poor measure of early or moderate disease. It only drops once the surviving retinal island has shrunk past a critical point.11Ovid. THE NATURAL HISTORY OF FULL-FIELD STIMULUS THRESHOLD DECLINE IN CHOROIDEREMIA Deeper phenotyping using microperimetry, dark-adapted testing, and autofluorescence area measurement provides a more sensitive picture of where a patient stands and how quickly things are changing.23Eye. Prospective deep phenotyping of choroideremia patients using multimodal structure-function approaches Getting these assessments right is not just academic. If and when gene therapy becomes widely available, the decision about when to treat will hinge on exactly these kinds of measurements.